Kaylene J. Simpson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kaylene J. Simpson has a total of 898 co-authors. Here are the top co-authors by number of shared publications:
- Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
64 shared publications - Angel F. Lopez
Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia
64 shared publications - Brooks A. Benard
Stanford University
64 shared publications - C. Glenn Begley
11Begley Biotech Consulting, Wallington, Victoria, Australia
64 shared publications - Daniel Thomas
School of Medicine, College of Health, Adelaide University, Adelaide, Australia
64 shared publications - Denis Tvorogov
Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia
64 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Research Square
Translational reprogramming drives chromosomal instability during tumorigenesis
Chromosomal instability (CIN) is a defining hallmark of cancer that drives genomic evolution, yet the molecular mechanisms triggering CIN during early tumorigenesis remain poorly defined. Here, we identify translation as a critical gatekeeper of chromosomal integrity during tumor initiation. Using models of tumorigenesis driven by SMAD4 loss, we integrate CRISPR-Cas9 screening, polysome profiling, and in vivo approaches to demonstrate that this disruption triggers a selective translational reprogramming that impairs mitotic fidelity. Specifically, SMAD4 deficiency alters the global translational landscape and suppresses translation of key mitotic regulator CDK11B. Re-expression of the mitosis-specific isoform CDK11B-p58 rescues these defects and suppresses tumorigenesis, establishing it as a primary effector in this pathway. Importantly, patient tumor analyses reveal a robust correlation between SMAD4 and CIN markers across multiple cancer types. Collectively, our findings uncover a translationally mediated axis of CIN, offering a new mechanism for CIN-driven tumor initiation.
- 29 September 2026
- Published by Springer Nature in Research Square
Open AccessTranslational reprogramming drives chromosomal instability during tumorigenesis
Chromosomal instability (CIN) is a defining hallmark of cancer that drives genomic evolution, yet the molecular mechanisms triggering CIN during early tumorigenesis remain poorly defined. Here, we identify translation as a critical gatekeeper of chromosomal integrity during tumor initiation. Using models of tumorigenesis driven by SMAD4 loss, we integrate CRISPR-Cas9 screening, polysome profiling, and in vivo approaches to demonstrate that this disruption triggers a selective translational reprogramming that impairs mitotic fidelity. Specifically, SMAD4 deficiency alters the global translational landscape and suppresses translation of key mitotic regulator CDK11B. Re-expression of the mitosis-specific isoform CDK11B-p58 rescues these defects and suppresses tumorigenesis, establishing it as a primary effector in this pathway. Importantly, patient tumor analyses reveal a robust correlation between SMAD4 and CIN markers across multiple cancer types. Collectively, our findings uncover a translationally mediated axis of CIN, offering a new mechanism for CIN-driven tumor initiation.
- Open Access
- 24 September 2026
- Published by Elsevier in SLAS Discovery
- Vol. 44, 100341
Probing and painting to get the full picture of macrophage polarisation
- 24 September 2026
- Published by Elsevier in SLAS Discovery
- Vol. 44, 100341
Open AccessProbing and painting to get the full picture of macrophage polarisation
- Open Access
- 23 July 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (17) , 6299-6319
RAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability
The nucleolus is organized around actively transcribed ribosomal RNA genes (rDNA), where high RNA polymerase I (Pol I) activity creates intrinsic susceptibility to replication stress and DNA damage. Here, we identify the DNA translocase RAD54L as a critical regulator of the nucleolar DNA damage response (nDDR) to rDNA double-strand breaks (DSBs) and replication stress. We show that RAD54L localizes to the nucleolus under basal conditions and is recruited to nucleolar caps following CRISPR-Cas9-induced rDNA-DSBs to promote repair. RAD54L loss results in persistent RAD51 foci, increased nucleolar γH2AX, and micronuclei formation, indicating defective resolution of rDNA lesions and genome instability. Under baseline conditions and replication stress induced by the Pol I transcription inhibitor CX-5461, RAD54L limits the accumulation of ssDNA and coordinates nDDR signaling. We further show that rDNA-DSBs induce RNA polymerase II-dependent RNA-DNA hybrids (R-loops) at intergenic rDNA regions, which facilitate nucleolar reorganization and cap formation and repair factor recruitment. Together, these findings establish RAD54L as a key regulator that coordinates replication stress response and rDNA repair, maintaining rDNA stability and genome integrity.
- 23 July 2026
- Published by Springer Nature in The EMBO Journal
- Vol. 45 (17) , 6299-6319
Open AccessRAD54L coordinates the nucleolar DNA damage response to maintain rDNA stability
The nucleolus is organized around actively transcribed ribosomal RNA genes (rDNA), where high RNA polymerase I (Pol I) activity creates intrinsic susceptibility to replication stress and DNA damage. Here, we identify the DNA translocase RAD54L as a critical regulator of the nucleolar DNA damage response (nDDR) to rDNA double-strand breaks (DSBs) and replication stress. We show that RAD54L localizes to the nucleolus under basal conditions and is recruited to nucleolar caps following CRISPR-Cas9-induced rDNA-DSBs to promote repair. RAD54L loss results in persistent RAD51 foci, increased nucleolar γH2AX, and micronuclei formation, indicating defective resolution of rDNA lesions and genome instability. Under baseline conditions and replication stress induced by the Pol I transcription inhibitor CX-5461, RAD54L limits the accumulation of ssDNA and coordinates nDDR signaling. We further show that rDNA-DSBs induce RNA polymerase II-dependent RNA-DNA hybrids (R-loops) at intergenic rDNA regions, which facilitate nucleolar reorganization and cap formation and repair factor recruitment. Together, these findings establish RAD54L as a key regulator that coordinates replication stress response and rDNA repair, maintaining rDNA stability and genome integrity.
- Open Access
- 20 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43
From complexity to clarity: Building dashboards for hit selection in high throughput screens
- 20 July 2026
- Published by Elsevier in SLAS Discovery
- Vol. 43
Open AccessFrom complexity to clarity: Building dashboards for hit selection in high throughput screens
- 15 May 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (4-5) , 446-461
Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile
Low‐grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor responses to chemotherapy, MEK inhibitors, and hormonal therapies, highlighting the need for alternative strategies. This study aimed to identify novel therapeutic targets in NSMP LGSOC. A high‐throughput drug screen of 3,436 compounds (including FDA‐approved, clinically tested, and investigational agents) was conducted across 12 LGSOC and one control ovarian epithelial cell line. EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK‐mutant lines in combination with standard‐of‐care chemotherapy agents, carboplatin and paclitaxel. EGFR expression was assessed using RNA sequencing, DNA methylation profiling, and immunohistochemistry in primary tumors, followed by survival analysis based on expression levels. Unsupervised clustering of drug response data revealed subtype‐specific vulnerabilities, with EGFR inhibitors showing marked cytotoxicity in all five NSMP lines (robust Z ‐score ≤ −2), and minimal activity in MAPK‐ and USP9X ‐mutant lines. EGFR inhibitors (avitinib, AV‐412) showed selective, low‐dose synergy with standard‐of‐care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK‐mutant lines. NSMP tumors showed elevated EGFR mRNA and EGFR protein expression, associated with poor survival, advanced disease stage, and peritoneal involvement, and inversely correlated with MAPK mutations. These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype. © 2026 The Pathological Society of Great Britain and Ireland.
- 15 May 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (4-5) , 446-461
Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile
Low‐grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor responses to chemotherapy, MEK inhibitors, and hormonal therapies, highlighting the need for alternative strategies. This study aimed to identify novel therapeutic targets in NSMP LGSOC. A high‐throughput drug screen of 3,436 compounds (including FDA‐approved, clinically tested, and investigational agents) was conducted across 12 LGSOC and one control ovarian epithelial cell line. EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK‐mutant lines in combination with standard‐of‐care chemotherapy agents, carboplatin and paclitaxel. EGFR expression was assessed using RNA sequencing, DNA methylation profiling, and immunohistochemistry in primary tumors, followed by survival analysis based on expression levels. Unsupervised clustering of drug response data revealed subtype‐specific vulnerabilities, with EGFR inhibitors showing marked cytotoxicity in all five NSMP lines (robust Z ‐score ≤ −2), and minimal activity in MAPK‐ and USP9X ‐mutant lines. EGFR inhibitors (avitinib, AV‐412) showed selective, low‐dose synergy with standard‐of‐care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK‐mutant lines. NSMP tumors showed elevated EGFR mRNA and EGFR protein expression, associated with poor survival, advanced disease stage, and peritoneal involvement, and inversely correlated with MAPK mutations. These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype. © 2026 The Pathological Society of Great Britain and Ireland.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
(A) Representative FACS gating strategy for tracking cell-cycle in JJN3 cells. (B) Percentage of JJN3 cells within sub-G1 phase (n = 3). Error bars represent mean. +/- SEM. (C) Percentage viability of JJN3 cells treated with VPR8 and/or QVD. Error bars represent mean +/- SD (n = 3). (D) Time spent in each phase of cell cycle, quantifying kinetics of JJN3-PIP-FUCCI cells. Each circle represents an individual cell, n = 2 biological replicates. Error bars represent median +/- 95% confidence interval. Significance calculated using Mann-Whitney t-test, with measurements from individual cells pooled from 2 independent experiments (**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S3 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of DU145-eGFP-tubulin cells treated with DMSO, undergoing mitotic spindle formation and cytokinesis. Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data File 1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Drug Synthesis pathway, Supplementary movie legends
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Movie S2 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Representative movie of JJN3-PIP-FUCCI cells treated with 500nM VPR8, showing a cell that is mitotic but doesn't undergo cytokinesis (dark blue arrowhead), or a cell that is mitotic and dies (pink arrowhead). Mitotic phases indicated by colours as follows: green (G1), yellow (G2M), red (S). Time (hr:min).
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity
Putative DCAFs used for myeloma loss of representation screen